알레르기성 비염 치료제 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Allergic Rhinitis Drugs Market generated USD 13.7 billion in 2024 and is projected to expand at a CAGR of 3.9% between 2025 and 2034. The growing prevalence of allergic rhinitis cases among both children and adults continues to be a primary driver of market growth. Rising exposure to various allergens, including pollen, dust mites, pet dander, and mold, combined with increasing urbanization and environmental pollution, is amplifying the occurrence of allergic rhinitis globally. As more people become aware of the condition and its long-term effects, the demand for effective medications and advanced treatment options is witnessing a steady uptick.

The introduction of novel therapies, including dual-action and combination drugs that target multiple symptoms, is creating significant opportunities for pharmaceutical companies to expand their product portfolios. Furthermore, the development of advanced drug delivery methods, such as nasal sprays and dissolvable tablets, is enhancing patient compliance and driving product adoption. Growing healthcare spending, coupled with better diagnostic technologies, is enabling early detection and timely management of allergic rhinitis, further accelerating the market's expansion. An increasing focus on personalized medicine and targeted immunotherapies is also reshaping the market landscape as patients and healthcare providers seek long-term solutions beyond symptomatic relief.

The market is categorized based on the type of disease into perennial allergic rhinitis and seasonal allergic rhinitis. In 2024, perennial allergic rhinitis accounted for a dominant 58.3% share of the global market. The higher prevalence of chronic allergic rhinitis, typically triggered by indoor allergens like dust mites, mold, and pet dander, is fueling the demand for ongoing treatment regimens. Patients suffering from perennial allergic rhinitis often require long-term management strategies, including combination therapies and immunotherapies, to keep symptoms under control. These therapies, which integrate antihistamines and corticosteroids, are gaining widespread traction due to their ability to provide sustained relief, making them highly preferred among chronic allergy sufferers worldwide.

In terms of treatment types, the market is segmented into antihistamines, corticosteroids, immunotherapy, decongestants, combination therapies, and others. Antihistamines emerged as the leading segment, valued at USD 5.5 billion in 2024, owing to their extensive use in managing common allergic rhinitis symptoms such as sneezing, nasal congestion, itching, and runny nose. The broad availability of antihistamines in various forms, including oral tablets, nasal sprays, and eye drops, coupled with their quick symptom relief, makes them a top choice among patients. The increasing inclination toward over-the-counter (OTC) antihistamine products for immediate relief is also propelling segment growth.

The U.S. Allergic Rhinitis Drugs Market reached USD 5.2 billion in 2024, driven by the rising incidence of allergic conditions triggered by environmental factors and lifestyle changes. Growing urbanization and heightened exposure to allergens have significantly contributed to the surge in allergic rhinitis cases. As public awareness of allergic rhinitis grows and early diagnosis becomes more accessible, a larger patient pool is actively seeking treatment options. The robust demand for advanced and effective therapies is boosting the U.S. market, with pharmaceutical companies focusing on expanding product innovations to address evolving patient needs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising awareness about allergic reactions and available treatment options
    • 3.2.1.2 Increasing prevalence of allergic rhinitis
    • 3.2.1.3 Technological advancements in the field of allergy diagnosis and treatment
    • 3.2.1.4 Growing pollution levels coupled with rise in respiratory disorders
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated allergic rhinitis treatments
    • 3.2.2.2 Similarity of symptoms with other diseases
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Perennial allergic rhinitis
• 5.3 Seasonal allergic rhinitis

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Antihistamines
• 6.3 Corticosteroids
• 6.4 Immunotherapy
  • 6.4.1 Subcutaneous immunotherapy (SCIT)
  • 6.4.2 Sublingual immunotherapy (SLIT)
• 6.5 Decongestants
• 6.6 Combination therapy
• 6.7 Other treatment types

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription
• 7.3 OTC

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Nasal
• 8.4 Intravenous
• 8.5 Intraocular

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Children
• 9.3 Adults
• 9.4 Geriatric

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Italy
  • 11.3.5 Spain
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 ALK-Abello
• 12.2 Bayer
• 12.3 Boehringer Ingelheim
• 12.4 Dr. Reddy’s Laboratories
• 12.5 GlaxoSmithKline
• 12.6 Glenmark Pharmaceuticals
• 12.7 Merck
• 12.8 Mylan (Viatris)
• 12.9 Sanofi
• 12.10 Stallergenes Greer
• 12.11 Sun Pharmaceuticals
• 12.12 Teva Pharmaceutical Industries
• 12.13 Unichem Laboratories